Paysign Stock Falls 19% After Plasma Customer Moves 113 Centers to Another Processor

Paysign (Nasdaq: PAYS) fell 18.9% on Tuesday, Nov. 10, 2026, closing at $10.14 from a previous close of $12.51, on volume about 4.6 times normal. The S&P 500 ETF (SPY) fell 0.37% that session.

The decline followed news in the company's 8-K filed the evening before, which attached its third-quarter earnings release. In it, Chief Executive Mark Newcomer said a plasma customer had told the company it would move payment processing for 113 centers to another provider where it has a banking relationship. Paysign said the centers generated trailing 12-month revenue of $11.3 million and gross profit of $5.2 million, and it estimated a fourth-quarter impact of $1.5 million in revenue and $700 thousand in gross profit.

Plasma exposure is the focus

Plasma revenue rose 7.5% to $13.83 million in the quarter, while the company's plasma center count fell by 33 over the past 12 months to 562. Pharma revenue, by contrast, more than doubled to $16.62 million.

Company keeps its revenue outlook

Paysign reiterated full-year 2026 revenue guidance of $114.0 million to $117.0 million and raised its guidance for gross margin, net income, diluted EPS and Adjusted EBITDA. Chief Financial Officer Jeff Baker said the company expects to exceed its prior full-year profitability outlook even after accounting for the transition. The company said the transition does not change its 2027 growth expectations for patient affordability.

Third-quarter results

Total revenue rose 42.6% to $30.80 million, and net income reached $6.74 million, or $0.11 per diluted share, compared with $2.22 million, or $0.04, a year earlier. Cash stood at $34.54 million with no bank debt.

The filings do not state how analysts or investors weighed the plasma news against the raised profit outlook.